September 15, 2020
1 min read
Save

Phase 2 study of AU-011 for primary choroidal melanoma underway

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The first patient has been dosed in a phase 2 clinical trial investigating safety and efficacy of suprachoroidal administration of AU-011 as a potential treatment for primary choroidal melanoma, according to a press release.

Aura Biosciences is the licensing partner of Clearside Biomedical for the development of AU-011 for the treatment of primary choroidal melanoma. Aura is using Clearside’s SCS microinjector to deliver the treatment, the release said.

AU-011 passed the safety review for the first dose escalation cohort, which noted no adverse events.

“With this trial initiation, we are on track to have three product candidates delivered via our SCS microinjector in four clinical trials this year,” Thomas A. Ciulla, MD, MBA, chief medical officer and chief development officer of Clearside, said in the release.